CN113286587A - 用于治疗iv型胶原病的联苯磺酰胺化合物 - Google Patents

用于治疗iv型胶原病的联苯磺酰胺化合物 Download PDF

Info

Publication number
CN113286587A
CN113286587A CN201980079773.4A CN201980079773A CN113286587A CN 113286587 A CN113286587 A CN 113286587A CN 201980079773 A CN201980079773 A CN 201980079773A CN 113286587 A CN113286587 A CN 113286587A
Authority
CN
China
Prior art keywords
subject
pharmaceutical composition
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980079773.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·科梅尔斯
C·詹金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Traville Treatment Co
Original Assignee
Traville Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traville Treatment Co filed Critical Traville Treatment Co
Publication of CN113286587A publication Critical patent/CN113286587A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201980079773.4A 2018-10-04 2019-10-03 用于治疗iv型胶原病的联苯磺酰胺化合物 Pending CN113286587A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US62/741,270 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US62/853,904 2019-05-29
US201962894559P 2019-08-30 2019-08-30
US62/894,559 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Publications (1)

Publication Number Publication Date
CN113286587A true CN113286587A (zh) 2021-08-20

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079773.4A Pending CN113286587A (zh) 2018-10-04 2019-10-03 用于治疗iv型胶原病的联苯磺酰胺化合物

Country Status (13)

Country Link
US (1) US11207299B2 (https=)
EP (1) EP3860594B1 (https=)
JP (2) JP7524167B2 (https=)
KR (1) KR102902972B1 (https=)
CN (1) CN113286587A (https=)
AU (1) AU2019354784B2 (https=)
BR (1) BR112021006132A2 (https=)
CA (1) CA3114434A1 (https=)
ES (1) ES3057657T3 (https=)
IL (1) IL281965B1 (https=)
MA (1) MA53817A (https=)
MX (1) MX2021003606A (https=)
WO (1) WO2020072814A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017985A (zh) 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106637A (zh) * 2014-08-21 2017-08-29 康德生物医疗技术公司 用于疾病预防和治疗的方法和组合物
WO2018071784A1 (en) * 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
US20220048900A1 (en) 2018-12-21 2022-02-17 Travere Therapuetics, Inc. Amorphous sparsentan compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106637A (zh) * 2014-08-21 2017-08-29 康德生物医疗技术公司 用于疾病预防和治疗的方法和组合物
WO2018071784A1 (en) * 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice", HEARING RESEARCH, vol. 341, 21 August 2016 (2016-08-21), pages 100 - 108 *
FRANK.T.L VAN DER LOOP，ET AL,: "Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation", KIDNEKIDNEY INTERNATIONAL, vol. 58, no. 5, 1 November 2000 (2000-11-01), pages 1870 - 1875, XP055653101, DOI: 10.1111/j.1523-1755.2000.00358.x *

Also Published As

Publication number Publication date
JP7524167B2 (ja) 2024-07-29
MX2021003606A (es) 2021-08-16
BR112021006132A2 (pt) 2021-07-20
US20200147050A1 (en) 2020-05-14
JP2024133735A (ja) 2024-10-02
MA53817A (fr) 2021-08-11
EP3860594B1 (en) 2025-10-01
CA3114434A1 (en) 2020-04-09
AU2019354784A1 (en) 2021-04-15
IL281965A (en) 2021-05-31
WO2020072814A1 (en) 2020-04-09
JP2022514152A (ja) 2022-02-10
AU2019354784B2 (en) 2025-07-10
IL281965B1 (en) 2026-04-01
US11207299B2 (en) 2021-12-28
ES3057657T3 (en) 2026-03-03
KR20210081338A (ko) 2021-07-01
KR102902972B1 (ko) 2025-12-22
EP3860594A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
KR102528435B1 (ko) 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
KR102547164B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
EP2444078B1 (en) Use of amides of mono and dicarboxylic acids in the treatment of renal diseases
JP2026069500A (ja) 線維症を治療するためのシクロスポリン類似体の使用
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
US20220133702A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
AU2024343419A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination